Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | DRAM Pricing · Big Tech Demand · Earnings Upgrades / 2026-01-19 Research
  • [Research] Samsung Biologics (207940) – iM Securities | US Site Operation · K-CDMO Policy Support · Order Pipeline Optimization / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Hyundai Motor | LTA · Premium Product Mix · Blended ASP / 2026-07-14 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Rockville Revenue Recognition · Guidance Revision Potential · Songdo Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Up-cycle · Large-Scale CapEx · Target Price Upgrade / 2026-07-08 Research
  • [IR] SK hynix (000660 / SKHY) – Q2 2026 Earnings Presentation / 2026-07-29 IR Room
  • [Research] Samsung SDI (006400) – Hana Securities | SDC Stake Monetization Pursuit · Up to KRW 11T Liquidity · Valuation Multiples Re-rating / 2026-02-20 Research
  • [Research] SK hynix (000660 / SKHY) – iM Securities | Memory ASP · Server Demand · Earnings Upgrades / 2026-03-31 Research

[Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · PHLX Inclusion · Valuation Re-rating / 2026-06-01

Posted on June 1, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Mirae Asset Securities

Analyst : Younggun Kim

Investment Rating : BUY (Maintained)

Target Price : KRW 3,800,000 (Maintained)

Core Momentum : The planned US ADR listing is expected to expand global investor access and create potential passive inflows through PHLX index inclusion, supporting a valuation re-rating that narrows the multiple discount to global semiconductor peers.

📊 1. [Valuation & Key Financial Metrics]

  • Equity Research Date: June 1, 2026
  • Investment Rating: BUY (Maintained) / Target Price: KRW 3,800,000 (Maintained)
  • Current Price (as of 26/5/29): KRW 2,333,000 / Upside Potential: 62.9%
  • Operating Profit (26F, KRW bn): 289,785 / Consensus Operating Profit (26F, KRW bn): 256,000
  • EPS Growth (26F, %): 441.9 / MKT EPS Growth (26F, %): 239.0
  • P/E (26F, x): 7.3 / MKT P/E (26F, x): 9.2 / KOSPI: 8,476.15
  • Market Capitalization (KRW bn): 1,662,735 / Shares Outstanding (mn shares): 713 / Float Ratio (%): 74.9
  • Foreign Ownership (%): 51.4 / Beta (12M) Daily Return: 1.73
  • 52-Week Low / High (KRW): 204,500 / 2,333,000
  • FY 2026F Estimates: Revenue KRW 366,486 bn, Operating Profit KRW 289,785 bn, Net Income KRW 228,203 bn, EPS KRW 319,452, ROE 96.7%, P/E 7.3x, P/B 4.7x, Dividend Yield 0.2%
  • FY 2027F Estimates: Revenue KRW 530,534 bn, Operating Profit KRW 420,470 bn, Net Income KRW 321,079 bn, EPS KRW 450,509, ROE 62.9%, P/E 5.2x, P/B 2.5x, Dividend Yield 0.3%

🚀 2. [Market Opportunities & Business Outlook]

  • The company confidentially submitted a registration statement for an ADR listing public offering to the US SEC on March 24, targeting a listing within the year through a new share issuance method of up to 2.5% (17.9 million shares).
  • Following the ADR listing, inclusion in the Philadelphia Semiconductor Index (PHLX) is anticipated, which could bring passive inflow distributions supported by weight caps on top-tier index constituents.
  • Operating profits for 2Q26 and 26F are estimated at KRW 67 trillion and KRW 290 trillion respectively, outperforming recent 1-month market consensus, while its 27F P/E of 5.2x and P/B of 2.4x highlight absolute undervaluation compared to PHLX averages.
  • Given strict commercial law revisions regarding treasury stock disposals following its full treasury stock cancellation, the ADR issuance is most likely to proceed via new share issuance tailored to maintain the largest shareholder’s stake requirements.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates SK hynix as an enterprise combining solid fundamental earnings growth with dual catalysts: a US ADR listing and expectations of PHLX index inclusion, capturing global passive fund inflows and valuation re-rating. This perspective focuses on closing the multiple discount gap relative to global semiconductor peers despite its robust earnings power.

To determine whether this investment thesis is actively unfolding, key monitoring items include tracking the progress of the US ADR public offering timeline and the finalization of new share issuance scale within the year. In addition, it is necessary to verify post-listing daily trading volume requirement of at least 1.5 million shares after 6 months of listing and monitor the visibility of PHLX index inclusion and passive inflow distribution during upcoming periodic rebalancings such as September 2027. These developments can be tracked through corporate earnings releases, official IR materials, and regulatory filings on DART/SEC.

📢 Disclaimer & Source Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports. Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor. Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | LTA · HBM Demand · Valuation Re-rating / 2026-05-27
Next Post: [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Long-term Exclusive Contracts · 2029 Target EPS · Structural ASP Hikes / 2026-06-01

Related Posts

  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Hikes · Server Product Mix · Target Price Revision / 2026-07-31 Research
  • [Research] Alteogen (196170) – Shinhan Securities | 2 Out-Licensing Deals in Q1 · Biogen Deal Analysis · Major Catalysts Ahead from April / 2026-03-27 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · Valuation Gap · Re-rating / 2026-03-25 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07 Research
  • [Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28 Research
  • [Research] Alteogen (196170) – Hana Securities | Core Business on Track · Favorable Deal Outlook · Keytruda Royalty Impact Reflected / 2026-02-19 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Acquisition Finalized · Guidance Revision Outlook · Tariff Resilience / 2026-04-02 Research
  • [Research] Celltrion (068270) – Daishin Securities | Merger Noise Resolution · Portfolio Expansion Leverage · CMO Revenue Visibility / 2026-05-19 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Solidigm Monetization · Shareholder Returns · Valuation Appeal / 2026-08-11 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | SDC Stake Monetization Pursuit · North America ESS & Europe EV Order Acceleration · Operating Profit Turnaround / 2026-04-29 Research
  • [Research] Hanwha Ocean (042660) – Kiwoom | Merchant Profit Driver · High-Price Mix Scale-Up · Naval & Offshore Orders / 2026-04-29 Shipbuilding
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Rockville Revenue Recognition · Guidance Revision Potential · Songdo Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] Samsung Biologics (207940) – Yuanta Securities | US Site Acquisition · Biosecure Act Beneficiary · Plant 6 & Campus 3 Expansion / 2026-01-07 Research
  • [Research] ABL Bio (298380) – Mirae Asset Securities | BBB Shuttle Re-rating · IGF1R Competitiveness · ABL001 Data Readout / 2026-03-26 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme